



Press Release

TheraPPI Bioscience Awarded Reputable French Tech Seed Label

TheraPPI Bioscience SAS is proud to announce that it has been awarded the French Tech Seed label, a recognition reserved for DeepTech startups less than three years old. This distinction acknowledges TheraPPI's remarkable technological innovation, astute management, and robust business model, marking a significant milestone in the company's journey.

January 08, 2024 – Lyon, France

The consortium Pouss@LYS in Lyon and Saint-Etienne, led by Sophie Julian from PULSALYS SAS, undertook a comprehensive assessment of TheraPPI Bioscience SAS ("TheraPPI"). Their thorough evaluation culminated in a favourable recommendation for the reputable French Tech Seed label on 14th December.

"We are honoured to receive the French Tech Seed label, which underscores our commitment to pioneering technological advancement and therapeutic innovation to patients," expressed Luc Otten, CEO of TheraPPI. "This recognition reaffirms the value of our technology, our proficient management practices, and our sustainable business model."

The French Tech Seed label signifies a noteworthy endorsement of TheraPPI's potential to make significant contributions to the burgeoning DeepTech sector. This achievement further solidifies the company's position as a frontrunner in pioneering solutions within the biotech and pharma industry.

- ends -

Notes:

About French Tech Seed Fund (<https://lafrenchtech.com/en/how-france-helps-startups/french-tech-seed-en/>)

The French Tech Seed Fund is a EUR400 million match fund, allowing Bpifrance to co-invest in hundreds of young deeptech startups. It aims to leverage private investment in technology startups in the post-maturation stage, in particular, deep tech startups that are less than three years old, with the goal of network co-funding.

About TheraPPI Bioscience :

TheraPPI is preclinical-stage biotech company which develops protein interaction-modifying drugs to offer patients better treatments in oncology, rare diseases and inflammation. TheraPPI has been incubated within Pulsalys (French TTO of Lyon-St Etienne).

TheraPPI's two first programs target a novel MAPK protein interaction discovered by the founder team at the CRCL (University Claude Bernard Lyon 1, Inserm, Centre Léon Bérard and CNRS) in Lyon, France, in collaboration with the C3D technology platform of Lyon (Centre for Drug Discovery and Development) and with the support of Hospices Civils de Lyon..

The prognosis of patients with advanced cancers remains poor. The MAPK signaling is hyperactivated in over 40% of human cancers and MAPK-activating mutations cause rare diseases. The efficacy of current MAPK Inhibitors is undercut by cancer resistance and by their inability to cure these rare diseases.

TheraPPI's lead program in oncology revolutionizes RAS-MAPK targeting: the new mode of action leverages three mechanisms with direct killing cancer cells, no resistance induction and activation of an anti-tumoral immune response.

TheraPPI's lead program aims to obtain a high rate of clinical responses, to circumvent cancer resistance and to improve the response of immunotherapies and thus to offer a better prognosis to patients with advanced cancer.

Read more: <https://tppibio.com/>

Follow us on LinkedIn: <https://www.linkedin.com/therappi-bioscience/>

Forward Looking Statements:

This press release includes forward-looking statements and assumptions which reflect the management's current views of future events and operations. These forward-looking statements involve certain significant risks and uncertainties, and actual results may (negatively or positively) differ substantially from the forward-looking statements described explicitly or implicitly by TheraPPI.

Contacts:

TheraPPI Bioscience

Luc Otten

CEO and co-founder

info@tppibio.com